Preview

Тазовая хирургия и онкология

Расширенный поиск

Химиотерапия больных метастатическим раком толстой кишки

https://doi.org/10.17650/2220-3478-2012-0-2-26-34

Полный текст:

Аннотация

Рак толстой кишки (РТК) занимает лидирующие позиции по заболеваемости и смертности от злокачественных опухолей. В 2008 г. в России зарегистрировано 55 719 новых случаев РТК и одновременно умерло по этой причине 37 911 больных. За последние десятилетия в лечении диссеминированного РТК достигнут значительный прогресс. Выросло число лечебных опций: от монотерапии 5-фторурацилом до комбинированных схем лечения с включением хирургического компонента. Среди больных с метастатическим раком была выделена группа больных с изолированным поражением печени, у которых проведение системной терапии и оперативного лечения позволяет достигнуть 5-летней выживаемости 40 %. Сегодня, основываясь на линических данных и данных молекулярного анализа, можно приблизиться к понятию индивидуализации» лечения больных данным заболеванием. В данном обзоре литературы проведен анализ результатов лекарственного лечения больных с етастатическим РТК, сформулирована рациональная тактика лечения в зависимости от цели проводимой терапии.

 

Об авторах

М. Ю. Федянин
ФГБУ РОНЦ им. Н.Н. Блохина РАМН, Москва
Россия


А. А. Трякин
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Россия


С. А. Тюляндин
ФГБУ РОНЦ им. Н.Н. Блохина РАМН, Москва
Россия


Список литературы

1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2008 г. Вестник Российского онкологического центра им. Н.Н. Блохина РАМН 2010. Том 21, № 2 (прил. 2).

2. Chau I. and Cunningham D. Treatment in advanced colorectal cancer: what, when and how? Br J Cancer 2009;100:1704−19.

3. Nordlinger B., van Cutsem E., Rougier P. et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 2007;43(14):2037−45.

4. Schellens J.H.M. Cancer clinical pharmacology. Oxford Univercity Press. 2006. p. 52.

5. Meta-analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 998;16:301−8.

6. Advanced colorectal cancer meta-analysis project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rates. J Clin Oncol 1992;10:904−11.

7. De Gramont A., Bosset J.F., Milan C., et al. Randomized trial comparing monthly lowdose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin ncol 1997; 15:808−15.

8. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301−8.

9. Maughan T.S., James R.D., Kerr D.J. et al. Preliminary results of multicenter randomized trail comparing 3 chemotherapy regimens (de Gramont, Lokich, and Raltitrexed) in metastatic colorectal cancer. Proceedings of American Society of clinical Oncology 1999;18:262a.

10. Pentheroudakis G., Twelves C. The rational development of capecitabine from the laboratory to the clinic. Anticancer Res 2002;22:3589−96.

11. Van Cutsem E., Twelves C., Cassidy J., et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097−106.

12. Hoff P.M., Ansari R., Batist G., et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282−92.

13. Fuchs C.S., Marshall J., Mitchell E., et al. Randomized, controlled trial of irinotecan

14. plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol 2007;30:4779−86.

15. Porschen R., Arkenau H.T., Kubicka S., et al. Phase III study of capecitabine plus xaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 2007;25:4217−23.

16. Dнaz-Rubio E., Tabernero J., Go’mez-Espan A., et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-Line therapy in metastatic colorectal cancer: final report of the spanish cooperative group for the treatment of

17. digestive tumors trial. J Clin Oncol 2007; 25:27.

18. Ducreux M., Bennouna J., Hebbar M., et al. Efficacy and safety findings from a randomized phase III study of capecitabine (X) + oxaliplatin (O) (XELOX) vs infusional 5-FU/LV + O (FOLFOX6) for metastatic colorectal cancer (MCRC). J Clin Oncol 2007;(Meeting Abstracts)25:4029.

19. Hochster H.S., Hart L.L., Ramanathan R.K. et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol 2008;26(21):3523−9.

20. Cunningham D., Pyrhonen S., James R.D., et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413−8.

21. Saltz L.B., Douillard J., Pirrotta N., et al. Combined analysis of two phase III randomized trials comparing irinotecan (C), fluorouracil (F), leucovorin (L) vs. F alone as first-line therapy of previously untreated metastatic colorectal cancer (MCRC). Proc ASCO 2000;19:242a.

22. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as firstline treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041−7. [Erratum, Lancet 2000;355:1372.].

23. Becouarn Y., Rougier P. Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer. Semin Oncol 1998;25(Suppl 5):23−31.

24. Raymond E., Buquet-Fagot C., Djelloul S., et al. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 1997;8:876−85.

25. De Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938−47.

26. Rothenberg M.L., Oza A.M., Bigelow R.H., et al. Superiority of oxaliplatin and fluorouracil−leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil−leucovorin: interim results of a phase III trial. J Clin Oncol 2003;21(11):2059−69.

27. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229−37.

28. Goldberg R.M., Sargent D.J., Morton R.F., et al. N9741: FOLFOX (oxaliplatin (Oxal)/5-fluorouracil (5-FU)/ leucovorin (LV) or reduced dose R-IFL (CPT-11 + 5-FU/LV) in advanced

29. colorectal cancer (CRC): final efficacy data from an intergroup study. J Clin Oncol 2004;22:Suppl:3621, abstract.

30. Colucci G., Gebbia V., Paolett G., et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol 2005;23 (22):4866−75.

31. Grothey A., Sargent D., Goldberg R.M., et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209−14.

32. Falcone A., Ricci S., Brunetti I., et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25:1670−6.

33. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335−42. 31. Saltz L.B., Clarke S., Diaz-Rubio E., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013−9.

34. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011−27.

35. Lu J., Gaudreault J., Novotny W., et al. A population pharmacokinetic model for bevacizumab. Clin Pharmacol Ther 2004;75:91(abstr PII-149).

36. Prewett M., Huber J., Li Y., et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999;59:5209−18.

37. Saltz L.B., Clarke S., Diaz-Rubio E., et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC). ASCO 2007 Gastrointestinal Cancers Symposium abst. 238.

38. Tebbutt N., Gebski V., Wilson K., et al. International randomised phase III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) in first line treatment of metastatic colorectal cancer (mCRC): final results of the AGITG MAX trial. European Journal of Cancer Supplements, 2009;7(2):321.

39. Van Cutsem E., Tabernero J., Lakomy R., et al. Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second line treatment of metastatic colorectal cancer (MCRC): results of a multinational phase III trail (EFC10262-VLOURE). Ann Oncol 2011;22(suppl 5):v18.

40. Mendelsohn J., Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21(14):2787−99.

41. Mayer A., Takimoto M., Fritz E., et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993;71(8):2454−60.40. De Roock W., Piessevaux H., De Schutter J., et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008;19:508−15.

42. Di Fiore F., Blanchard F., Charbonnier F., et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007;96:1166−9.

43. Lievre A., Bachet J.B., Boige V., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374−9.

44. Van Cutsem E., Lang I., Folprecht G., et al. Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): The influence of KRAS and BRAF biomarkers on outcome: Updated data from the CRYSTAL trial. J Clin Oncol 2010 Gastrointestinal Cancers Symposium; 281 (abstr.), p. 4000.

45. Bokemeyer C., Bondarenko I., Makhson A., et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27:663−71.

46. Van Cutsem E., Rougier P., Kohne C., et al. A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy as 1st line treatment for patients with metastatic colorectal cancer: results according to KRAS and BRAF mutation status. ECCO-ESMO Congress 2009. Abstract No: 6077.

47. Maughan T., Adams R.A., Smith C.G., et al. Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN). Europ J Cancer 2009;7(3):4(abstr 6LBA).

48. Douillard J.Y., Siena S., Cassidy J., et al. Randomized Phase 3 Study of Panitumumab

49. with FOLFOX4 vs FOLFOX4 Alone as Firstline Treatment in Patients with Metastatic

50. Colorectal Cancer: the PRIME Trial. Eur J Cancer 2009;7(3suppl):10LBA..

51. Tveit K., Guren T., Glimelius B., et al. Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: the NORDIC VII study (NCT00145314), by the Nordic Colorectal Cancer Biomodulation Group. Ann Oncol 2010;21(suppl 8):viii9.

52. Saltz L.B., Lenz H.J., Kindler H.L., et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007;25:4557−61.

53. Hecht J.R., Mitchell E., Chidiac T., et al. A Rabdomized phase IIIB trial of chemotherapy, bevacizumab and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 672−80.

54. Aschele C., Bergamo F., Lonardi S. Chemotherapy for operable and advanced colorectal cancer. Cancer Treatment Reviews 2009;35:509−16.

55. Weber S.M., et al. Survival after resection of multiple hepatic colorectal metastases. Ann Surg Oncol 2000;7:643−50.


Для цитирования:


Федянин М.Ю., Трякин А.А., Тюляндин С.А. Химиотерапия больных метастатическим раком толстой кишки. Тазовая хирургия и онкология. 2012;(2):26-34. https://doi.org/10.17650/2220-3478-2012-0-2-26-34

For citation:


Fedyanin M.Y., Tryakin A.А., Tjulandin S.A. Chemotherapy of metastatic colon cancer. Pelvic Surgery and Oncology. 2012;(2):26-34. (In Russ.) https://doi.org/10.17650/2220-3478-2012-0-2-26-34

Просмотров: 251


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2686-9594 (Online)